All In Biotech

Drug Trial Radar · NCT05765032

Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

An Open Label, Multicenter, Phase Ib/II Study of SHR-A1921 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

220

Actual

Start

Dec 30, 2022

Primary completion

Apr 30, 2025

Study completion Feb 28, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is a multicentre phase Ⅰb/Ⅱ Study to evaluate the efficacy and safety of SHR-A1921 in combination with other anti-cancer agents in patients with advanced solid tumors

Conditions

  • Advanced Solid Tumor

Interventions

  • SHR-A1921;Drug

    Drug: SHR-A1921 administered as an IV infusion Drug: Adebrelimab administered as an IV infusion Drug: Carboplatin administered as an IV infusion Drug: Cisplatin administered as an IV infusion Drug: Bevacizumab administered as an IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) over the DLT period. (Phase 1b)Time frame: up to 21 days of cycle 1
  2. Determination of Recommended Phase II dose (RP2D) (Phase 1b)Time frame: Up to 21 days of cycle 1
  3. Objective Response Rate as Assessed by the Investigator according to RECIST v1.1(Phase II)Time frame: From baseline to progressive disease or death (approximately 1 year)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute& Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.